$0.86
−3.36%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$0.91
From 52W high−91.91%
Volume312972.00
Market cap$13.51M
P/E (TTM)—
P/S (TTM)7.0x
Div yield—
Key dataNov 4, 2026
Open
$0.91
From 52W high
−91.91%
Volume
312972.00
Market cap
$13.51M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.2x
P/E (TTM)
—
RSI (14)
33.2
MomentumView details →
1D Return
−3.36%
YTD Return
−82.95%
SummaryUpdated Jun 1, 2026
Radiopharm Theranostics Limited (ASX:RAD) is a clinical-stage biotechnology company founded in 2021 and based in Carlton, Australia. The company recently went public in December 2024, representing one of the newest entrants in the radiopharmaceutical space. Radiopharm focuses on developing next-generation radiopharmaceutical products that combine diagnostic imaging with targeted therapeutic applications, addressing areas of high unmet medical need in oncology.
Similar companies
Latest newsMore news →
Radiopharm Theranostics Ltd expects to initiate a Phase 3 imaging trial of RAD101 for recurrent brain metastases from solid tumors in the first quarter of 2027.2d agoRadiopharm Theranostics Ltd said it had a successful end-of-phase 2 meeting with the U.S. Food and Drug Administration for RAD101.2d agoRadiopharm Theranostics dosed the first patient in the second cohort of its Phase 1/2a clinical trial of BetaBart (RV-01), a radiopharmaceutical therapeutic for B7-H3 expressing solid tumors, at a 70 mCi dose, marking the first such therapeutic developed in its joint venture with MD Anderson Cancer Center.70d ago